Interest in plasmapheresis longevity research has grown alongside a broader shift toward functional healthcare – care that is predictive, preventive, and proactive rather than reactive. Plasmapheresis, also known as therapeutic plasma exchange (TPE), has long been used in medicine to treat autoimmune and neurological conditions by removing harmful substances from the bloodstream. More recently, scientists have begun studying whether this same process, by clearing age-associated proteins from circulating plasma, may also relate to biological aging.
This article explains how plasmapheresis works, why researchers think it may connect to aging biology, and what current human evidence actually shows. As with most areas of longevity science, the use of plasmapheresis for anti aging purposes is still emerging – promising in early studies, but not yet an established or FDA-approved anti-aging treatment.
What Is Plasmapheresis (Therapeutic Plasma Exchange)?
Plasmapheresis is a medical procedure in which blood is drawn from the body, run through a machine that separates plasma (the liquid portion of blood) from red and white blood cells and platelets, and then returned to the body along with a replacement fluid – typically a solution containing purified albumin, saline, or donor plasma. The original plasma, along with whatever it was carrying (antibodies, inflammatory proteins, and other circulating factors), is discarded.
The procedure is performed through an IV or catheter, generally takes one to three hours, and is monitored closely for fluid balance, electrolytes, and clotting factors. Plasmapheresis has established clinical uses in autoimmune neurological disease, certain kidney conditions, and hyperviscosity syndromes – our complete guide to plasmapheresis walks through the procedure itself in more detail. Its use in the context of plasmapheresis for longevity is a newer, distinct application still being investigated in research settings rather than as routine clinical practice.
The Biological Rationale Connecting Plasma Exchange to Aging
The idea that plasma composition changes with age is well documented. As people get older, plasma tends to accumulate higher levels of pro-inflammatory proteins and other factors associated with age-related decline in tissue repair capacity – a pattern researchers sometimes describe as part of “inflammaging.” Laboratory research using animal models has explored whether removing a portion of this aged plasma, and replacing it with a neutral solution such as saline and albumin, might shift the plasma proteome toward a more youthful profile.
In a widely cited study from researchers at UC Berkeley, replacing roughly half of old mice’s plasma with a saline-albumin solution was associated with improved measures of tissue repair across muscle, liver, and brain tissue – effects that were comparable to or greater than those seen with young plasma infusion in the same model (Mehdipour et al., Aging, 2020). A related study from the same group found that this plasma dilution approach was associated with improved cognitive measures and reduced markers of neuroinflammation in aged mice (Mehdipour et al., GeroScience, 2021).
These findings shifted scientific interest away from the idea of “young blood” transfusion and toward a different hypothesis: that removing age-elevated, potentially harmful plasma factors – rather than adding youthful ones – may be the more relevant mechanism. This is the biological rationale underlying human research into plasmapheresis longevity applications: TPE, using albumin as a replacement fluid, is one existing clinical tool that approximates this dilution effect in people.
What the Early Human Evidence Shows
Human research in this area remains limited, and results have been mixed. It is important to represent this honestly: this is an early-stage, actively evolving field, not an established anti-aging therapy.
Human biological age pilot data. A clinical study of patients undergoing therapeutic plasma exchange identified a panel of circulating protein biomarkers associated with “biological noise” that correlated with chronological age and cognitive status, and reported that TPE was associated with reductions in these markers consistent with a younger biological age profile in some participants (Kim et al., GeroScience, 2022).
Randomized trial with multi-omics analysis. A more recent single-blind, placebo-controlled trial in healthy adults over age 50 compared TPE alone, TPE combined with intravenous immunoglobulin (IVIG), and monthly TPE against a sham control. Using combined epigenetic, proteomic, metabolomic, and immune biomarker data, the trial reported an average reduction in biological age of roughly 2.6 years in the TPE-plus-IVIG group relative to baseline, alongside signals of reduced systemic inflammation (Fuentealba et al., Aging Cell, 2025).
A contrasting result. Not all human data point the same direction. A separate crossover trial in healthy blood donors undergoing repeated plasmapheresis – without replacement using young plasma or concentrated albumin – found no statistically significant change in epigenetic age as measured by established epigenetic clocks (Borsky et al., Scientific Reports, 2025). This finding is a useful reminder that the replacement fluid, dosing schedule, and population studied all appear to matter, and that results are not yet consistent across trials.
Related clinical trial context. Separately, the AMBAR trial – a randomized, controlled, multi-year trial in patients with mild-to-moderate Alzheimer’s disease – tested plasma exchange with albumin replacement and reported a slower rate of cognitive and functional decline compared to sham treatment over 14 months (Boada et al., Alzheimer’s & Dementia, 2020). While this trial targeted a specific disease population rather than general aging, it remains one of the larger controlled human datasets on plasma exchange with albumin replacement and is often referenced in the broader longevity research discussion.
Taken together, this body of research suggests a plausible biological connection between plasma exchange and markers of aging, but the human evidence is still small in scale, inconsistent across study designs, and far from conclusive. See our related article on regenerative medicine for anti-aging for how this fits alongside other longevity-focused approaches.
What Patients Should Know: Limitations of the Current Evidence
Before considering plasmapheresis for longevity, it is worth understanding what the science does and does not yet support:
- Most of the strongest mechanistic evidence still comes from animal studies; human trials are few, small, and use varying protocols (replacement fluid type, frequency, and added agents like IVIG all differ between studies).
- Results across human trials have been mixed – some report favorable shifts in biological age biomarkers, while at least one well-designed trial found no significant change in epigenetic age.
- Plasmapheresis is an invasive medical procedure with real risks, including infection at the access site, blood pressure changes, electrolyte imbalances, and allergic reactions to replacement fluids. It requires clinical supervision.
- No regulatory body has approved plasmapheresis specifically as an anti-aging or longevity treatment; its approved uses remain in autoimmune, neurological, and hematologic disease.
- Longevity biomarkers such as epigenetic clocks are themselves an evolving research tool, and improvements in these markers have not yet been definitively linked to longer healthy lifespan in humans.
Because of this, plasmapheresis is best understood today as a promising area of longevity research rather than a proven anti-aging intervention. Anyone considering it should do so as part of a broader, personalized conversation with a qualified healthcare provider, informed by comprehensive bloodwork and an individual risk assessment.
Frequently Asked Questions
What is plasmapheresis longevity research actually studying?
It is studying whether removing plasma and replacing it with a neutral fluid, such as saline and albumin, changes biomarkers associated with biological aging – including inflammatory proteins, epigenetic markers, and proteomic signatures – compared with a person’s baseline or with a placebo procedure.
Is plasmapheresis for anti aging purposes FDA-approved?
No. Plasmapheresis is FDA-cleared for specific medical uses such as autoimmune neurological disorders and certain blood conditions. Its use for anti-aging or longevity purposes is investigational and is not an approved indication.
How is plasmapheresis different from a young plasma infusion?
Plasmapheresis removes a person’s own plasma and typically replaces it with albumin and saline rather than plasma from a younger donor. Research suggests that removing age-associated factors, rather than adding young plasma, may be the more relevant mechanism behind observed effects in animal studies.
Does plasmapheresis reverse aging?
No study has shown that plasmapheresis reverses aging. Some early human trials report modest, temporary shifts in biological age biomarkers, while other trials have found no significant change. Research indicates this is an area requiring further study, not a demonstrated anti-aging cure.
What are the risks of plasmapheresis?
Reported risks include low blood pressure, electrolyte imbalances, citrate-related symptoms (such as tingling), allergic reactions to replacement fluids, and infection risk associated with catheter access. A qualified provider should evaluate individual risk before any procedure.
How often would plasmapheresis need to be repeated for any longevity-related effect?
Research protocols have varied widely, from single sessions to biweekly or monthly courses over several months. There is no established, validated schedule for longevity purposes, and any effects observed in trials have not been shown to be permanent.
Can plasmapheresis be combined with other longevity-focused testing?
Some functional healthcare clinics pair procedures like plasma exchange with comprehensive lab panels and longevity-focused diagnostics to help track biomarkers over time, though this pairing itself is a clinical approach rather than a proven combined therapy.
Who should not undergo plasmapheresis?
People with certain bleeding disorders, active infections, unstable cardiovascular conditions, or allergies to replacement fluid components may not be appropriate candidates. A full medical evaluation is necessary before any decision is made.
Key Takeaways
- Plasmapheresis longevity research explores whether removing and replacing plasma affects biomarkers associated with biological aging.
- The biological rationale centers on clearing pro-inflammatory, age-associated plasma proteins rather than adding “young” plasma.
- Early human trials show mixed results: some report reduced biological age markers, while others find no significant epigenetic change.
- This remains an emerging, early-stage research area – not an FDA-approved or clinically established anti-aging treatment.
- Individual evaluation, comprehensive bloodwork, and guidance from a qualified provider are essential before considering any plasma-based procedure.
Curious how plasmapheresis and plasma exchange fit into a personalized, science-backed wellness plan? Explore the Ways2Well Longevity Lab or schedule a consultation to discuss whether comprehensive diagnostics and functional healthcare options are right for you.
References
- Boada M, López OL, Olazarán J, et al. “A randomized, controlled clinical trial of plasma exchange with albumin replacement for Alzheimer’s disease: Primary results of the AMBAR Study.” Alzheimer’s & Dementia, 2020;16(10):1412–1425. DOI: https://doi.org/10.1002/alz.12137
- Mehdipour M, Skinner C, Wong N, et al. “Rejuvenation of three germ layers tissue by exchanging old blood plasma with saline-albumin.” Aging (Albany NY), 2020;12(10):8790–8819. DOI: https://doi.org/10.18632/aging.103418
- Mehdipour M, Mehdipour T, Skinner CM, et al. “Plasma dilution improves cognition and attenuates neuroinflammation in old mice.” GeroScience, 2021;43(1):1–18. DOI: https://doi.org/10.1007/s11357-020-00297-8
- Kim D, Kiprov DD, Luellen C, et al. “Old plasma dilution reduces human biological age: a clinical study.” GeroScience, 2022;44(6):2701–2720. DOI: https://doi.org/10.1007/s11357-022-00645-w
- Fuentealba M, Kiprov D, et al. “Multi-Omics Analysis Reveals Biomarkers That Contribute to Biological Age Rejuvenation in Response to Single-Blinded Randomized Placebo-Controlled Therapeutic Plasma Exchange.” Aging Cell, 2025. DOI: https://doi.org/10.1111/acel.70103
- Borsky P, Holmannova D, Parova H, et al. “Human clinical trial of plasmapheresis effects on biomarkers of aging (efficacy and safety trial).” Scientific Reports, 2025;15. DOI: https://doi.org/10.1038/s41598-025-05396-0
Author: Ways2Well Editorial Team
Reviewed by: Scientific Advisory Board member